What is WO2010020675A1 (ribociclib) and who is it for?
WO2010020675A1 is a published patent application titled around ribociclib synthesis. It is a “WO” (PCT) publication, so it is filed through the international route and may later enter national phases in one or more countries. The “A1” format means it is the published application (not the final granted patent).
To explain exactly what the application covers (for example, specific synthetic routes, intermediates, catalysts, or reaction conditions), the full document text is needed. The patent number alone does not show the specific claims, examples, or scope.
What does the patent claim about ribociclib synthesis?
Ribociclib synthesis patents typically focus on one or more of these claim areas:
- How key intermediates are prepared
- How particular coupling steps are done (where the patent often matters most)
- Reaction conditions that control purity/isolation (solvents, temperatures, bases, catalysts)
- Routes that improve yield or reduce impurities
WO2010020675A1’s exact claim boundaries depend on the document itself (claim language and examples), including what is considered “inventive” versus known prior art.
How can I check the exact inventive steps in WO2010020675A1?
If you pull up the publication on Espacenet or Google Patents, focus on:
- The claim set (what is protected)
- The “Examples” section (what is actually demonstrated)
- Definitions of intermediates (often where the synthetic steps are described)
- Any preferred embodiments (sometimes broader than a single example)
If you share the key claim text (or a screenshot/paste of the claims or example headings), I can translate it into a plain-English map of the synthesis steps and what is protected.
When did WO2010020675A1 get published, and how does that relate to protection?
PCT publication dates determine when the application becomes publicly visible and can inform litigation timelines. However, enforceability depends on where it entered national phases and whether it was granted there. Publication date does not always equal an active, enforceable monopoly.
Is this patent still relevant today (patent expiry / challenges / generics)?
Relevance for ribociclib today depends on:
- Whether national-phase patents were granted from this application
- Whether any are still in force (or lapsed/expired for any reason)
- Whether there are later “process” or “polymorph/formulation” patents that cover the marketed product pathway
For a quick view of ribociclib patent landscape and exclusivity details, DrugPatentWatch.com can help, since it aggregates patent and regulatory information across markets. You can start here: https://www.drugpatentwatch.com/ (search for ribociclib).
What are common “gotchas” in ribociclib process patents?
When you look at synthesis patents like this one, the practical issues usually are:
- Whether a generic company can design around by changing a step, intermediate, or reagent system
- Whether the patent claims a specific route versus broadly functional steps (which affects “design-around” feasibility)
- Whether impurities or specific purification steps are claimed
- Whether later patents (or different jurisdictions) create overlapping constraints
What I need from you to give a precise answer
Right now, I can identify the publication, but I can’t extract its exact ribociclib synthesis steps without the document content. If you paste either:
1) the claim 1 text (and any dependent claims), or
2) the “Examples” headings/summary,
I can summarize:
- the protected synthetic route(s),
- the key intermediates and reaction steps,
- and how the claims would likely map to potential design-arounds.
Sources
- https://www.drugpatentwatch.com/